A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Active, not recruiting · Phase 3 · NCT06508658
Conditions: Diffuse Large B-Cell Lymphoma
At a glance
- Research payments reported, 2025
- $522,833
- U.S. investigators named
- 14
- Sites paid
- 12
- Planned or actual enrollment
- 379
About the trial
- Sponsor
- Genmab (with AbbVie)
- Tested
- Epcoritamab (drug), Rituximab (drug), Lenalidomide (drug), Oxaliplatin (drug), Gemcitabine (drug)
- Dates
- Started 2024-08-13; completion 2028-03
- Results posted
- Not yet
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Around 360 adult participants with R/R D…
From ClinicalTrials.gov, last updated 2026-04-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $522,833 in research payments for this study in 2025 (52 payments).
Products named: Epkinly
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David Berz, MD, PHD, MPH Hematology & Oncology · Los Angeles, CA
- Tycel J. Phillips, M.D. Hematology · Duarte, CA
- Leslie L. Popplewell, M.D. Hematology · Duarte, CA
- Karng S. Log, DO Hematology & Oncology · Littleton, CO
- Jawad Sheqwara, M.D Hematology & Oncology · Waycross, GA
- Seo-hyun Kim, M.D. Hematology · Chicago, IL
- Tulio E. Rodriguez, M.D. Hematology & Oncology · Zion, IL
- Shruti Singh, MD Hematology & Oncology · Dyer, IN
- Nisha I. Sainani, M.D. Radiology · Boston, MA
- Jennie Y. Law, MD Hematology & Oncology · Baltimore, MD
- Darla K. Liles, MD Hematology & Oncology · Greenville, NC
- Mitchell S. Cairo, MD Pediatric Hematology & Oncology · Hawthorne, NY
- Lindsey Fitzgerald Hematology & Oncology · Salt Lake City, UT
- Stephan D. Kendall, M.D. Medical Oncology · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Valkyrie Clinical Trials Inc $194,841
- University of Maryland $106,152
- City of Hope National Medical Ctr $61,500
- Rush University Medical Center, IL $34,255
- Iho Corporation $28,595
- East Carolina University $26,159
- Western Inst for Biomedical Researc $20,500
- Ns Imaging Related Services Inc $15,420
- Sisters of Charity of Leavenworth $13,250
- New York Medical College $10,641
- $4,880
- Henry Ford Health Hospital, MI $4,000
- Northwest Cancer Center PC $2,640
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.